País: Estats Units
Idioma: anglès
Font: NLM (National Library of Medicine)
DACARBAZINE (UNII: 7GR28W0FJI) (DACARBAZINE - UNII:7GR28W0FJI)
Hospira, Inc.
DACARBAZINE
DACARBAZINE 10 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection, USP is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents. Dacarbazine for Injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.
NDC 61703-327-22, 200 mg of Dacarbazine for Injection, USP per vial as sterile dacarbazine packaged in individual cartons.
Abbreviated New Drug Application
DACARBAZINE- DACARBAZINE INJECTION, POWDER, FOR SOLUTION HOSPIRA, INC. ---------- DACARBAZINE FOR INJECTION, USP Rx only WARNING It is recommended that Dacarbazine for Injection be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. 2. 3. 4. DESCRIPTION Dacarbazine for Injection, USP is a colorless to an ivory colored solid which is light sensitive. Each vial contains 200 mg of dacarbazine (the active ingredient), citric acid monohydrate and mannitol. Dacarbazine for Injection, USP is reconstituted and administered intravenously (pH 3 to 4). Dacarbazine is an anticancer agent designated chemically as 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide with the following structural formula: CLINICAL PHARMACOLOGY After intravenous administration of Dacarbazine for Injection, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. In a Hemopoietic depression is the most common toxicity with Dacarbazine for Injection (see WARNINGS). Hepatic necrosis has been reported (see WARNINGS). Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity. patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours. Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations dacarbazine is not appreciably bound to human plasma protein. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole-4- carboxamide (AIC) is a major metabolite of dacarbazine exc Llegiu el document complet